AI-designed vaccine shows promise in human trials
AI-designed vaccine shows promise in human trials
Updated at: June 6, 2026 at 07:30 AM
In a groundbreaking development for medical science, researchers have successfully tested the first vaccine component entirely designed by artificial intelligence.
Led by scientists at the University of Cambridge and DIOSynVax, this innovative study focuses on a 'future-proof' vaccine called pEVAC-PS.
By analyzing the genetic codes of all known sarbecoviruses, the AI identified shared features across the entire virus family.
This allows the vaccine to prime the immune system to recognize not only current variants but also future mutations that haven't emerged yet.
During a Phase I clinical trial involving 39 volunteers, the DNA vaccine was administered via a needle-free jet, proving safe and well-tolerated.
Participants demonstrated promising immune responses against a broad range of coronaviruses.
This shift from reactive to proactive development could change how we handle pandemics.
Following these successful initial results, researchers are planning larger studies to confirm these findings and move closer to a new era of global pandemic preparedness.
